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In practice




Background: Population-based cancer screening has been established for 
several types of cancer in Australia and internationally. Screening may perform 
differently in practice from randomised controlled trials, which makes evaluating 
programs complex. 
Materials and methods: We discuss how to assess the evidence of benefits 
and harms of cancer screening, including the main biases that can mislead 
clinicians and policy makers (such as volunteer, lead-time, length-time and 
overdiagnosis bias). We also discuss ways in which communication of risks can 
inform or mislead the community.
Results: The evaluation of cancer screening programs should involve balancing 
the benefits and harms. When considering the overall worth of an intervention 
and allocation of scarce health resources, decisions should focus on the net 
benefits and be informed by systematic reviews. Communication of screening 
outcomes can be misleading. Many messages highlight the benefits while 
downplaying the harms, and often use relative risks and 5-year survival to 
persuade people to screen rather than support informed choice. 
Lessons learned: An evidence based approach is essential when evaluating 
and communicating the benefits and harms of cancer screening, to minimise 
misleading biases and the reliance on intuition.
Introduction
Cancer screening is the systematic search for cancer in people who have no 
signs or symptoms of the disease, to identify those who probably have cancer 
and those who do not. Individuals with a positive test result undergo further 
investigations, and those who are diagnosed with cancer receive treatment that 
aims to improve the length and quality of their life. Because screening involves 
testing people who are asymptomatic, there is the potential to turn otherwise 
healthy people into patients by sending them through a cascade of events that 
can be beneficial as well as harmful. Thus, there is a strong ethical imperative to 
ensure that a cancer screening program results in net benefit to the population 
and that we are using scarce resources efficiently and rationally. 
The health benefits of cancer screening include minimising morbidity and 
mortality due to cancer, and reducing the risk of developing the disease. 
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• An evidence based approach to cancer 
screening is essential 
• Both benefits and harms (including false 
positives, overdiagnosis and overtreatment) 
need to be estimated
• Evaluating cancer screening remains difficult 
because of important biases; randomised 
trials are the most effective way to control 
for lead-time, length-time, overdiagnosis 
and volunteer bias
• Communication about screening should 
always present benefits and harms using 
absolute risks and mortality
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However, there is also the potential for harm. The most 
frequent harm is a false-positive result – where an 
abnormality is detected but, with further investigation, no 
cancer is found. The cumulative risk of a false-positive 
result increases with each screening mammogram and can 
lead to unnecessary investigations that can cause physical 
pain and scarring, and negatively affect quality of life.1 
The most serious harm is overdiagnosis – where an 
individual is diagnosed with cancer, and typically receives 
treatment, even though the cancer was not destined to 
cause symptoms or death. Overdiagnosis occurs because 
some screen-detected cancers grow very slowly, or 
are nonprogressive or even regressive, and competing 
mortality means that an individual may die from another 
cause before the cancer causes symptoms.
Potential for bias in 
cancer screening 
Two critical forms of bias affect estimates of the effects 
of cancer screening: lead-time bias and length-time bias. 
Lead-time bias arises when we compare the survival – the 
time from diagnosis to death – of people screened for 
cancer to those not screened (Figure 1). Screening detects 
cancer earlier in the natural history of the disease and 
therefore moves the diagnosis to an earlier point in time. So 
even if cancer screening is not effective, and therefore does 
not reduce mortality, it may appear to increase survival 
because of lead-time bias. 
Length-time bias can also arise in analyses of cancer 
screening (Figure 2). Cancer screening tests are typically 
able to detect slow-growing cancers with a longer 
preclinical phase (that is, a longer time before signs and 
symptoms develop), which tend to have a better prognosis. 
In contrast, more rapidly growing cancers with a shorter 
preclinical phase and poorer prognosis are more likely 
to present clinically than be detected by screening. An 
extreme form of length-time bias is called overdiagnosis 
bias, where survival rates improve because, as a result of 
attending screening, people are diagnosed with a cancer 
that would never have caused symptoms during their 
lifetime. Randomised controlled trials in which the endpoint 




A systematic review has shown that the public 
overestimates the benefits and underestimates the harms 
of screening for breast, cervical and prostate cancer.2 
Advocates of screening may emphasise its advantages 
while minimising (or even ignoring) the downsides.3 
Efforts may go beyond persuasion and make people feel 
irresponsible and guilty to convince them to have cancer 
screening. A more balanced communication of potential 
benefits and harms facilitates informed choice, where 
individuals make their own decision about participating 
in screening.4 There is arguably an ethical imperative to 
provide evidence about benefits and harms of screening 
to potential participants, and to policy makers who must 
choose between different population health strategies 
within budgetary constraints.5,6 
Figure 1. Lead-time bias
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When communicating the potential mortality benefit 
of cancer screening, the first step is to ensure that an 
appropriate outcome is used. Survival rates (typically 
reported as 5-year survival) should be avoided because 
they can be misleading. Five-year survival is defined as 
the proportion of people who are still alive 5 years after 
diagnosis of cancer. Although survival has an intuitive 
appeal, it cannot be used to establish the efficacy of 
screening because of lead- and length-time bias (see 
Figures 1 and 2). The mortality rate, which is the number 
of people who die from the cancer divided by the size 
of the population, is a better outcome to evaluate the 
effectiveness of cancer screening. Mortality does not 
consider the time from diagnosis to death and is unaffected 
by length-time bias.
Even when the mortality rate is used to communicate 
benefit, the way this is reported can influence health 
behaviours.7 Health statistics are often reported as relative 
risks rather than absolute risks, which affect perception 
of the benefits and harms of screening.8 For example, 
screening for prostate cancer using the prostate-specific 
antigen (PSA) test gives a 20% relative reduction in 
prostate cancer mortality among men aged 55 to 69 years 
according to one estimate.9 If we consider the absolute risk 
reduction, however, the benefit is less impressive. For every 
1000 men aged 55 to 69 years who are screened every 
2 to 7 years across a 10-year period, 0 to 1 men avoid 
dying from prostate cancer compared with unscreened 
men. This represents a reduction from 5 deaths among 
every 1000 unscreened men to 4 to 5 deaths among 
1000 screened men.9 
Evaluating whether to implement a 
cancer screening program 
Evaluating a cancer screening program involves estimating 
benefits and harms to determine net benefits, and then 
considering whether the magnitude of net benefits justifies 
the resources required to run a program.10 An evaluation 
should be conducted by an independent organisation 
that considers both high-quality scientific evidence and 
other factors such as available resources and population 
preferences. This requires data on patient-important health 
outcomes, cost-effectiveness and public engagement to 
elicit values and preferences, using deliberative methods.11 
The best method for estimating the benefit and harms of 
cancer screening is a randomised controlled trial, but this 
may lack applicability to clinical practice.
Cancer screening trials require a large sample size – 
often hundreds of thousands of participants – to ensure 
control of potential confounding factors and detection of 
a difference between groups. This is resource intensive 
and makes it difficult to achieve adequate recruitment. 
Participants may prefer a particular group than the one to 
which they are randomised, which can influence screening 
attendance.12 Resulting loss of fidelity causes bias towards 
the null, reducing statistical power.13 Long-term follow-up 
over many years is necessary to evaluate both the benefit 
of mortality reduction and harms due to overdiagnosis. 
These prerequisites of cancer screening trials – long 
duration, large sample size and adequate adherence to the 
trial protocol – can make them impractical, and they may 
be particularly challenging to undertake once a program 
is established.
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Any decision to implement a cancer screening 
program should be based on evidence of net benefit to 
the population, demonstrated by a reduction in all-cause 
mortality – that is, evidence that people are, on balance, 
likely to live longer if they participate in screening. A 
reduction in overall mortality may not be found because 
any decrease in cancer-specific mortality is offset or even 
overtaken by deaths due to downstream effects of the 
screening test, diagnosis or treatment.14 Increased mortality 
from other causes might occur as a result of:
•	 The invasive test needed to confirm diagnosis after a 
positive screening test (e.g. prostate biopsies)15,16
•	 Psychological consequences of the disease label 
(e.g. increased rates of myocardial infarction and of 
suicide after prostate cancer diagnosis)17
•	 Consequences of treatment of overdiagnosed cancers 
(e.g. deaths due to surgical complications and radiation 
effects after treatment for breast cancer).18 
Few randomised controlled trials conducted to date 
have had sufficient power to show an effect on all-cause 
mortality. Solutions to this include pooling trial data by 
meta-analysis or analysing epidemiological trends. Where 
there is uncertainty, new randomised controlled trials that 
are powered to detect a difference in all-cause mortality 
may be needed. Although such trials need to be very large, 
they are justified given the expense of population screening 
programs when we are uncertain if there is true benefit to 
society. Trial costs may be substantially reduced if they are 
conducted within large, national observational registries, 
which may even make them comparable to the cost of 
current screening trials.19 
Evaluating a cancer screening 
program after implementation
Although randomised trial data are often used to inform 
decisions about whether a screening program should 
be implemented, they are rarely used for evaluation of 
benefits and harms of the program once it is established. 
Uncertainty may remain about specific components of the 
strategy, and the screening technology itself often changes 
over time – for example, 3D mammography for breast 
cancer screening20 or liquid cytology for cervical cancer 
screening.21 Advances in technology are often incorporated 
into clinical practice without adequate evaluation of their 
effects on important health outcomes such as cancer-
specific mortality or overdiagnosis.20,22
There may also be changes in cancer prevention 
and treatment after the implementation of a screening 
program. For example, improvements in breast cancer 
treatment23 have meant that the mortality benefit of current 
mammography screening is likely to be smaller than that 
first observed in the original screening trials. Improvements 
in prevention can also decrease the incidence of cancer. 
For example, implementation of human papillomavirus 
vaccination programs has brought a decline in high-grade 
cervical abnormalities and reduced estimated mortality 
benefits from cervical cancer screening.24 Given the 
improved outlook, these cancer screening programs may 
not be as necessary as they once were.
Ongoing evaluation of screening programs is possible 
using pragmatic randomised trials within the program, with 
the eligible population randomised to different screening 
strategies.25 The comparison may be between two 
screening interventions26,27 or screening to no screening 
where there is proposed expansion to the program.28 
Evaluating the benefits and harms of screening through 
randomised comparisons could theoretically be widely 
adopted within new and existing screening programs, if 
there is the political will – the previous examples show 
that communities readily accept the randomisation.26-28 
Observational studies are more commonly used to evaluate 
existing cancer screening programs. Although they may 
be more applicable than randomised controlled trials, they 
are more prone to biases (which usually favour screening). 
Nevertheless, observational studies may be useful for 
monitoring benefits and harms over time.29 Regardless 
of the study design, the critical requirement for screening 
evaluation is that the evidence enables us, with minimal 
bias and reasonable certainty, to quantify the benefits 
and harms.
Conclusions
An evidence based approach to cancer screening is 
essential to maximise benefits (improved length and 
quality of life) while minimising the harms to individuals 
(false positives, overdiagnosis and overtreatment) and 
opportunity costs to society. Evaluating cancer screening 
remains difficult due to important biases, so we must 
continue to implement randomised controlled trials to 
generate the best evidence on the magnitude of benefits 
and harms with reasonable certainty. Those responsible for 
communicating cancer screening can do better by always 
providing absolute risks and ensuring transparent reporting 
of benefits and harms without using 5-year survival rates or 
relative risks.
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